CEO Niklas Prager and the management team will present a summary of the company's strategy, platforms and projects and finances after the transformation of the company in 2016. After the presentation there will be a break-out session on the presented projects.
Time: Thursday 23 February, at 2pm - 4pm CEST
Venue: IVAs Conference Center, Grev Turegatan 16, Stockholm
Invitation for: Institutional investors, analysts and media
The event will also be available after the meeting through Medivir's website; www.medivir.com
Registration for investors, analysts and journalistsTo participate, please register at; http://www.financialhearings.com/event/10014, no later than 20 February.
For further information, please contact:
Medivir develops innovative pharmaceutical products for the treatment of cancer. The company specialises in protease inhibitor research and nucleotide/nucleoside science and conducts research in all stages of the drug development process, from original idea to clinical phase III studies. Its development work is done both in-house and through partnerships.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/medivir-capital-markets-meeting-on-23-february-2017-300402370.html